PROGRAM
All Times are EST
Program is subject to change

Friday, February 11, 2022

7:50 am	Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Thomas A. Albini, MD
	Session I: Genetics, Histopathology, and Imaging in Non-Exudative AMD Moderators: Philip J. Rosenfeld, MD, PhD; Giovanni Gregori, PhD; and Zohar Yehoshua, MD, MHA Panelists: Gregory S. Hageman PhD; James G. Fujimoto, PhD; K. Bailey Freund, MD; Christine A. Curcio, PhD; Ruikang Wang, PhD; Lawrence A. Yannuzzi, MD; Giovanni Staurenghi, MD; and Frank G. Holz, MD
8:00	Chromosome 10q26–driven AMD is Associated with Reduced Expression of HTRA1 in Human RPE Gregory S. Hageman, PhD
8:10	Ultrahigh Resolution OCT in AMD James G. Fujimoto, PhD
8:20	How Understanding the Histologic Basis of Retinal Imaging Findings in AMD Can Improve Current and Future Patient Outcomes K. Bailey Freund, MD
8:30	Histology and Clinical Lifecycle of Hyperreflective Foci: Implications for AMD Outcome Measures Christine A. Curcio, PhD
8:40	Optical Attenuation as the Contrasting Mechanism in OCT Imaging and its Applications for Quantifying Choroid and Detecting RPE Ruikang Wang, PhD
8:50	The Role of Optical Attenuation Coefficient (OAC) OCT Imaging and AMD Progression Philip J. Rosenfeld, MD, PhD
9:00	Detachment of the Retinal Pigment Epithelium: Life Cycle Lawrence A. Yannuzzi, MD
9:10	Extensive Macular Atrophy with Pseudodrusen: What We Know Giovanni Staurenghi, MD
9:20	MACUSTAR: Functional Impairment and Structural Features in Intermediate AMD Frank G. Holz, FEBO, FARVO
	Session II: Predicting Progression of AMD Moderators: Thomas A. Albini, MD; Sander R. Dubovy, MD; and Philip J. Rosenfeld, MD, PhD Panelists: Karl G. Csaky, MD, PhD; Emily Y. Chew, MD; Pearse A. Keane, MD; Ursula Schmidt-Erfurth, MD; and Aaron Y. Lee, MD, MSCI
9:30	The Role of Normal and Low Luminance Quantitative Contrast Sensitivity Function Testing in Predicting AMD Progression Karl G. Csaky, MD, PhD
9:40	Artificial Intelligence/Machine Learning/Deep Learning for Detecting AMD Features and for Predicting Progression to Late AMD Emily Y. Chew, MD
9:50	Clinically Applicable Deep-Learning Model for Detection and Quantification of Geographic Atrophy from Optical Coherence Tomography Pearse A. Keane, MD
10:00	Therapeutic Response Pattern of GA Lesion to Pegcetacoplan Ursula Schmidt-Erfurth, MD
10:10	Scaling Down and Scaling Up, Building Deep Learning Models for Double Layer Sign Detection Aaron Y. Lee, MD, MSCI
	Session III: Emerging Therapies for Non-Exudative AMD Moderators: Ninel Z. Gregori, MD; Nicolas A. Yannuzzi, MD; and Raquel Goldhardt, MD Panelists: David S. Boyer, MD; Amir H. Kashani, MD, PhD; Nadia K. Waheed, MD, MPH; Glenn J. Jaffe, MD; Peter K. Kaiser, MD; and Justis P. Ehlers, MD
10:20	Inhibition of Connexin43 for the Treatment of AMD and Diabetic Retinopathy David S. Boyer, MD
10:30	ReCLAIM-2: Baseline Characteristics Including Planned iRORA to cRORA and Ellipsoid Zone Methodologies Justis P. Ehlers, MD
10:40	One Year Follow-up in a Phase 1/2a Clinical Trial of an Allogeneic RPE Cell Bioengineered Implant for Advanced Dry Age-Related Macular Degeneration Amir H. Kashani, MD, MPH
10:50	CFI Supplementing Gene Therapy in GA Clinical Trial Update Nadia K. Waheed, MD, MPH
11:00	Measurement Parameters and Impact of Foveal Preservation in GA Progression in the GATHER-1 Trial Glenn J. Jaffe, MD
11:10	Novel OCT Findings Regarding “Nascent GA at Risk” and Directionality of GA Progression in the GATHER-1 Trial Peter K. Kaiser, MD
	Session IV: C3 Inhibition for the Teatment of Geographic Atrophy Moderators: Harry W. Flynn, Jr., MD; Philip J. Rosenfeld, MD, PhD; and Lawrence J. Singerman, MD Panelists: Ramiro Ribeiro MD, PhD; David R. Lally, MD; Jeffrey S. Heier, MD; Charles C. Wykoff, MD; Nancy Holekamp, MD; Usha Chakravarthy, MD; and David S. Boyer, MD
11:20	C3 Inhibition for GA: Background and Rationale Ramiro Ribeiro, MD, PhD
11:30	DERBY and OAKS Phase 3 Results David R. Lally, MD
11:40	A Deeper Dive into the DERBY and OAKS Phase 3 Results Jeffrey S. Heier, MD
11:50	Discussion
12:00 pm	Panel Discussion on Translating the Results of Clinical Trials to the Treatment of Nonexudative AMD in the Clinics Moderators: Philip J. Rosenfeld, MD, PhD and Lawrence J. Singerman, MD Panelists: Pravin U. Dugel, MD; Robyn Guymer MBBS, PhD; SriniVas R. Sadda, MD; Karl G. Csaky MD, PhD; Emily Y. Chew, MD; Ramiro Ribeiro, MD PhD; Frank Holz, MD; Glenn J. Jaffe, MD; Pearse A. Keane, MD; Ursula Schmidt-Erfurth, MD; Nadia K. Waheed, MD; Peter K. Kaiser, MD; and Jeffrey S. Heier, MD
	Session V: OCT Imaging and Risk Factors for Exudative AMD Moderators: Jorge A. Fortun, MD, PhD; Omer Trivizki, MD, MBA; and Philip J. Rosenfeld, MD, PhD Panelists: SriniVas R. Sadda, MD; David Sarraf, MD; Giuseppe Querques, MD; Usha Chakravarthy, MD; Fenghua Wang, MD; and Nancy Holekamp, MD
12:30	Choriocapillaris and Atrophy Associated with Neovascular AMD SriniVas R. Sadda, MD
12:40	Subretinal Fluid is Protective in Neovascular AMD: Fact or Fallacy? David Sarraf, MD
12:50	Non-Exudative Treatment-Naive Type 3 MNV Giuseppe Querques, MD
1:00	Ocular and Systemic Risk Factors for Progression to Exudation in the EDNA Trial Usha Chakravarthy, MD
1:10	The Predictable Factors for Recurrence of Polypoidal Choroidal Vasculopathy using OCT Anogiograhpy? Fenghua Wang, MD
1:20	Home OCT Based Tracking of Neovascular AMD Disease Dynamics and Treatment Response Nancy Holekamp, MD
1:30	Adjourn until Saturday Feb. 12th at 8:00 am

Saturday, February 12, 2022

7:50 am	Welcome and Overview Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Thomas A. Albini, MD
	Session VI: Emerging and Current Therapies for Exudative AMD Moderators: Janet L. Davis, MD; Thomas A. Albini, MD; and Jaclyn Kovach, MD Panelists: Daniel F. Martin, MD; Robert Bhisitkul, MD; Arshad M. Khanani, MD, MA; Jay S. Duker, MD; Andrew A. Moshfeghi, MD, MBA; Allen C. Ho, MD; Thomas A. Ciulla, MD, MBA; David M. Brown, MD; Charles C. Wykoff, MD, PhD; Peter A. Campochiaro, MD; David Eichenbaum, MD; Michael S. Ip, MD; and Rahul Khurana, MD
8:00	Long Term Outcomes in Neovascular AMD: What We Know and What We Don’t Daniel F. Martin, MD
8:10	Phase 1 Study of Intravitreal UBX1325: A Novel Agent Against Retinal Cell Senescence in AMD and DME Robert Bhisitkul, MD
8:20	6-month Results of a Tyrosine Kinase Inhibitor (Vorolanib) in a Bio-erodible Durasert Implant for Previously Treated Wet AMD: The DAVIO Trial Jay S. Duker, MD
8:30	Safety and Durability of Intravitreal Sunitinib Malate Depot (GB-102) in Wet Age-Related Macular Degeneration (ALTISSIMO, Phase 2B) Veeral S. Sheth, MD, MBA
8:40	Update on OTX-TKI Clinical Trials for Macular Disease Andrew A. Moshfeghi, MD, MBA
8:50	Update on 4D-150: Inhibition of VEGF A, B, C and PlGF Using Intravitreal, Dual Transgene AAV Gene Therapy for Neovascular AMD Arshad M. Khanani, MD, MA
9:00	RGX-314 Gene Therapy for Wet AMD Allen C. Ho, MD
9:10	The Suprachoroidal Space and Suprachoroidal Delivery for Clinicians Thomas A. Ciulla, MD, MBA
9:20	Update on the AAVIATE Phase 2 Study: Suprachoroidal RGX-314 in Neovascular AMD Rahul N. Khurana, MD
9:30	CANDELA: High Dose Aflibercept for Neovascular AMD David M. Brown, MD
	Ranibizumab Port Delivery System
9:40	2-Year Outcomes from the Phase 3 Archway Trial: Management of Neovascular Age-Related Macular Degeneration using the Ranibizumab Port Delivery System Charles C. Wykoff, MD, PhD
9:48	Long Term (3+ Year) Safety and Efficacy Data for the Port Delivery System David Eichenbaum, MD
9:56	Patient Level Analysis of the PDS versus Monthly Injections in Neovascular AMD Peter A. Campochiaro, MD
10:04	Discussion of Previous PDS Talks
10:10	A Treatment-Agnostic Analysis of the Long-Term Impact of IRF and SRF on Vision and Anatomy in Neovascular AMD in the HAWK and HARRIER Studies Michael S. Ip, MD
	Session VII: Dual Inhibition of Ang2 and VEGF for the Treatment of Exudative AMD and DME–An Update from the Faricimab Program Moderators: Philip J. Rosenfeld, MD, PhD; Lawrence J. Singerman, MD; and Harry W. Flynn, Jr., MD Panelists: Jeffrey S. Heier, MD; Robyn Guymer, MBBS, PhD; John A. Wells, III, MD; Thomas A. Albini, MD; Jennifer Sun, MD; Arshad Khanani, MD; and Usha Chakravarthy, MD
10:28	Overview of Faricimab for Exudative Retinal Diseases: nAMD, DME, and RVO Jeffrey S. Heier, MD
10:33	Faricimab Update in nAMD Robyn Guymer, MBBS, PhD
10:38	Faricimab in DME: 2 Year Data of the Yosemite/Rhine Phase 3 Studies John A. Wells, III, MD
10:48	Discussion
	Session VIII: Diabetic Retinopathy-Imaging and Staging Moderators: Justin H. Townsend, MD; Harry W. Flynn, Jr. MD; and Philip J. Rosenfeld, MD, PhD Panelists: Seung-Young Yu, MD; Jennifer Sun, MD; Anat Loewenstein, MD; Ramin Tadayoni, MD, PhD; Jonathan F. Russell, MD, PhD; and Toshinori Murata, MD, PhD
11:00	OCT Angiography in Diabetic Retinopathy Harry W. Flynn, Jr., MD
11:10	SS-OCTA Imaging for Determining Severity of Diabetic Retinopathy Seung-Young Yu, MD
11:20	Can Capillary Non-Perfusion on OCTA Be a Substitute for Color Photographs in DR Classification? Ramin Tadayoni, MD, PhD
11:30	Toward a New Staging System for Diabetic Retinopathy Using Widefield Swept-Source Optical Coherence Tomography Angiography Jonathan F. Russell, MD, PhD
11:40	Detection of Diabetic Retinopathy from Ultra-Wide Field Scanning Laser Ophthalmoscope Images: A Multi-Center Deep-Learning Analysis Anat Loewenstein, MD
11:50	Updating the Diabetic Retinal Disease Staging System Jennifer Sun, MD
	Session IX: Diabetic Retinopathy-Treatment Moderators: Harry W. Flynn, Jr., MD; Jayanth Sridhar, MD; and William E. Smiddy, MD Panelists: Michael A. Klufas, MD; Diana V. Do, MD; Mark R. Barakat, MD; Carl D. Regillo, MD; Arshad M. Khanani, MD, MA; and Peter K. Kaiser, MD
12:00 pm	APX3330, a Phase 2 Oral Drug Inhibiting Novel Target Ref-1 with a Dual Anti-VEGF and Anti-inflammatory MOA for the Treatment of Diabetic Retinal Diseases Peter K. Kaiser, MD
12:10	Phase 2 Results of THR-149 in Patients with DME: KALAHARI Study Part A Arshad M. Khanani, MD, MA
12:20	Suprachoroidal RGX-314 Gene Therapy for Diabetic Retinopathy Michael A. Klufas, MD
12:30	Intact Perifoveal Capillaries Confirmed by OCT-Angiography Leads to Successful Anti-VEGF Treatment for Diabetic Macular Edema and Branch Retinal Vein Occlusion Toshinori Murata, MD, PhD
12:40	Identifying Predictive Factors for Response to Aflibercept in the PANORAMA Study Diana V. Do, MD
12:50	52-week Results from KINGFISHER, a Phase III Study with q4w Dosing of Brolucizumab 6 mg in DME Mark R. Barakat, MD
1:00	Brolucizumab for the Treatment of DME: 100-Week Results from the Two Pivotal Phase III KESTREL and KITE studies Carl D. Regillo, MD
	Session X: Retinal and Choroidal Vasculopathies and Degenerations Moderators: Philip J. Rosenfeld, MD, PhD; Audina M. Berrocal, MD; and Stephen G. Schwartz, MD, MBA Panelists: Byron L. Lam, MD; Richard F. Spaide, MD; Darius M. Moshfeghi, MD; Carel B. Hoyng, MD; Quan Dong Nguyen, MD, MSc; Baruch D. Kuppermann, MD, PhD; Martin Friedlander, MD, PhD; and Prashanth G. Iyer, MD, MPH
1:10	What's New with MacTel2 Martin Friedlander, MD, PhD
1:20	Overview of Venous Overload Choroidopathy Richard F. Spaide, MD
1:30	Aflibercept for Retinopathy of Prematurity: Firefleye Trial Darius M. Moshfeghi, MD
1:40	Bruch's Membrane and Choriocapillaris Imaging in Sorsby Macular Dystrophy Prashanth G. Iyer, MD, MPH
1:50	Stargardt Disease, Towards Therapy Carel B. Hoyng, MD
2:00	Tinlarebant, an RBP4 (Retinol Binding Protein 4) Antagonist, for Stargardt Disease Quan Dong Nguyen, MD, MSc
2:10	Intravitreal Retinal Progenitor Cells for the Treatment of Retinitis Pigmentosa Baruch D. Kuppermann, MD, PhD
2:20	Treatment Update for Inherited Retinal Degenerations Byron L. Lam, MD
2:30	Post-Program Test and Closing Remarks